Want to see OMDA full AI Analyst Report?
OMDA Stock Chart & Stats
$14.14
-$4.40(-19.47%)
At close: 4:00 PM EDT
$14.14
-$4.40(-19.47%)
Day’s Range― - ―
52-Week Range$10.28 - $26.92
Previous Close$18.29
Volume2.54M
Average Volume (3M)1.20M
Market Cap
$1.33B
Enterprise Value$813.72M
Total Cash (Recent Filing)$211.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 06, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding59,448,505
10 Day Avg. Volume905,914
30 Day Avg. Volume1,198,822
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)4.01
Price to Sales (P/S)3.54
P/FCF Ratio54.46
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue2.87
Enterprise Value/Gross Profit4.34
Enterprise Value/Ebitda1.66K
Forecast
1Y Price Target
$22.89Price Target Upside61.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.28
Revenue Forecast (FY)$326.51M
Bulls Say, Bears Say
Bulls Say
Membership And Demand GrowthSustained member growth and strong revenue momentum indicate durable demand for Omada’s chronic-care subscription model. A growing enrolled base expands recurring revenue, improves unit economics over time, and strengthens go-to-market leverage with payers and employers, supporting multi-quarter growth.
Margin Expansion And Path To ProfitabilityRising gross margins and improving adjusted EBITDA reflect operating leverage from scale and AI-driven care efficiencies. Management’s upgraded EBITDA guidance signals momentum toward sustained profitability assuming continued retention, enabling reinvestment in product and sales while reducing reliance on external financing.
Strong Balance Sheet And Cash GenerationA debt-free balance sheet with substantial cash provides runway to invest in growth and withstand reimbursement or execution variability. Positive operating and free cash flow in 2025 further reduce refinancing risk and give flexibility to fund product expansion and channel development over the next several quarters.
Bears Say
GAAP Profitability Still NegativeDespite marked improvement, continued GAAP losses mean equity returns remain negative and profitability is not yet established. If growth or margin trends stall, the company could need to slow investments or raise capital, creating execution risk over the coming 2–6 months as results must prove sustainable.
Blended Revenue Per Member PressureCohort maturation that reduces per-member revenue is a structural headwind to near-term top-line growth. To offset this durable effect Omada must either expand members, increase multi‑condition penetration, or extract higher value via new services—each requiring sustained execution and time to materialize.
Competitive PBM / Channel DynamicsNon‑exclusive, multi‑vendor PBM channels limit pricing and placement power and make share gains incremental. Early-stage prescribing and channel ramps are expected to contribute materially only in 2027, leaving near-term dependency on core channels and exposing growth to competitive displacement risk.
Omada Health, Inc. News
OMDA FAQ
What was Omada Health, Inc.’s price range in the past 12 months?
Omada Health, Inc. lowest stock price was $10.28 and its highest was $26.91 in the past 12 months.
What is Omada Health, Inc.’s market cap?
Omada Health, Inc.’s market cap is $1.33B.
When is Omada Health, Inc.’s upcoming earnings report date?
Omada Health, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 32 days.
How were Omada Health, Inc.’s earnings last quarter?
Omada Health, Inc. released its earnings results on May 07, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.128 by $0.168.
Is Omada Health, Inc. overvalued?
According to Wall Street analysts Omada Health, Inc.’s price is currently Undervalued.
Does Omada Health, Inc. pay dividends?
Omada Health, Inc. does not currently pay dividends.
What is Omada Health, Inc.’s EPS estimate?
Omada Health, Inc.’s EPS estimate is 0.07.
How many shares outstanding does Omada Health, Inc. have?
Omada Health, Inc. has 59,448,505 shares outstanding.
What happened to Omada Health, Inc.’s price movement after its last earnings report?
Omada Health, Inc. reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.128. Following the earnings report the stock price went down -9.634%.
Which hedge fund is a major shareholder of Omada Health, Inc.?
Currently, no hedge funds are holding shares in OMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omada Health, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.89 (61.87% Upside)
$22.89 (61.87% Upside)
Blogger Sentiment
Bullish
OMDA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.70%
12-Months-Change
Fundamentals
Return on Equity
-2.81%
Trailing 12-Months
Asset Growth
114.47%
Trailing 12-Months
Company Description
Omada Health, Inc.
Omada Health is an American virtual health company that delivers evidence-based digital programs designed to manage common chronic ailments, including cardiometabolic, musculoskeletal, and behavioral health conditions, offering continuous support that bridges the gap between in-person medical appointments.
OMDA Company Deck
OMDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong growth and improving financial health: double-digit revenue growth (42% YoY), a key membership milestone (1.025M members, +51% YoY), margin expansion (GAAP 62%, non-GAAP 64%), positive adjusted EBITDA in Q1 and an upward revision to full-year guidance. Commercial momentum was highlighted by relationships with all three large PBMs and inclusion in Optum Rx and Lilly programs, alongside differentiated clinical evidence for the GLP-1 Care Track. Near-term headwinds are mostly transitional or tactical — cohort composition pressuring blended revenue per member, early-stage nature of some prescribing channels with material revenue expected more in 2027, modest device/shipping cost pressure (~$1M) and competitive multi-vendor PBM environments. Overall, the positives materially outweigh the manageable near-term challenges.View all OMDA earnings summariesOMDA Stock 12 Month Forecast
Average Price Target
$22.89
▲(61.87% Upside)
Technical Analysis
Teladoc
―
American Well
―
GoodRx Holdings
―
Privia Health Group
―
Hinge Health, Inc. Class A
―
Ownership Overview
3.58% Insiders
15.62% Mutual Funds
44.98% Other Institutional Investors
29.51% Public Companies and
Individual Investors